• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    2/17/22 8:11:46 AM ET
    $BFRA
    $BIOL
    $DRMA
    $INMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BFRA alert in real time by email

     

    Gainers

    • NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5 million. The company's, Q1 earnings came out 3 days ago.
    • Biofrontera (NASDAQ:BFRA) stock rose 11.85% to $3.49. The market value of their outstanding shares is at $98.9 million.
    • Paratek Pharmaceuticals (NASDAQ:PRTK) stock rose 9.76% to $4.27. The company's market cap stands at $214.3 million.
    • Revelation Biosciences (NASDAQ:REVB) stock rose 9.41% to $2.44. The market value of their outstanding shares is at $34.7 million.
    • INmune Bio (NASDAQ:INMB) stock rose 9.38% to $12.0. The market value of their outstanding shares is at $214.1 million.
    • Rhythm Pharmaceuticals (NASDAQ:RYTM) stock moved upwards by 7.08% to $7.1. The market value of their outstanding shares is at $356.9 million.

    Losers

    • 10x Genomics (NASDAQ:TXG) stock decreased by 23.7% to $72.5 during Thursday's pre-market session. The market value of their outstanding shares is at $8.0 billion. As per the news, the Q4 earnings report came out yesterday.
    • Marker Therapeutics (NASDAQ:MRKR) shares fell 19.03% to $0.5. The company's market cap stands at $41.5 million. The company's, Q4 earnings came out yesterday.
    • Larimar Therapeutics (NASDAQ:LRMR) stock fell 7.11% to $3.66. The market value of their outstanding shares is at $64.8 million.
    • Dermata Therapeutics (NASDAQ:DRMA) stock fell 6.35% to $1.18. The market value of their outstanding shares is at $9.8 million.
    • Orphazyme (NASDAQ:ORPH) stock fell 5.01% to $2.09. The market value of their outstanding shares is at $73.0 million.
    • Biolase (NASDAQ:BIOL) stock fell 4.45% to $0.39. The market value of their outstanding shares is at $60.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BFRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRA
    $BIOL
    $DRMA
    $INMB

    CompanyDatePrice TargetRatingAnalyst
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    10x Genomics Inc.
    $TXG
    12/11/2025Buy → Neutral
    Citigroup
    10x Genomics Inc.
    $TXG
    12/2/2025$20.00Overweight → Equal-Weight
    Morgan Stanley
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/25/2025$136.00Buy
    Citigroup
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/5/2025Outperform → Perform
    Oppenheimer
    10x Genomics Inc.
    $TXG
    9/11/2025$15.00Neutral
    Piper Sandler
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/14/2025$130.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/10/2025$97.00Buy
    Goldman
    More analyst ratings

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    * Director by Deputization Flynn James E bought $30,000,000 worth of shares (9,375,000 units at $3.20) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    8/4/25 6:28:33 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mcclurg Ronald W. bought $100,000 worth of shares (200,000 units at $0.50), increasing direct ownership by 82% to 444,117 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:47:21 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A bought $50,000 worth of shares (100,000 units at $0.50), increasing direct ownership by 9% to 1,161,289 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:38:47 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Manag

    2/26/26 7:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

    BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering

    2/25/26 8:59:46 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

    BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All s

    2/25/26 4:01:00 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    10x Genomics downgraded by Citigroup

    Citigroup downgraded 10x Genomics from Buy to Neutral

    12/11/25 8:24:15 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded 10x Genomics from Overweight to Equal-Weight and set a new price target of $20.00

    12/2/25 8:22:39 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BFRA
    $BIOL
    $DRMA
    $INMB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling

    1/26/21 5:26:59 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saxonov Serge sold $178,928 worth of shares (9,632 units at $18.58), decreasing direct ownership by 0.90% to 1,061,924 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/26 4:52:57 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Taich Adam sold $166,593 worth of shares (8,968 units at $18.58), decreasing direct ownership by 3% to 288,417 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/26 4:51:56 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Hindson Benjamin J. sold $145,379 worth of shares (7,826 units at $18.58), decreasing direct ownership by 2% to 424,779 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/26 4:51:01 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BFRA
    $BIOL
    $DRMA
    $INMB
    SEC Filings

    View All

    SEC Form S-3ASR filed by Rhythm Pharmaceuticals Inc.

    S-3ASR - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:37:52 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Rhythm Pharmaceuticals Inc.

    S-8 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:16:44 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Rhythm Pharmaceuticals Inc.

    10-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:02:04 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Financials

    Live finance-specific insights

    View All

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Manag

    2/26/26 7:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

    BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chie

    2/17/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

    PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, rep

    2/12/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

    6/3/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

    Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

    6/26/24 2:54:12 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFRA
    $BIOL
    $DRMA
    $INMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

    SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 5:46:11 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care